Agios Pharmaceuticals shares plunged more than 18 percent after the company discontinued development of an experimental drug for rare blood disorder due to side effects seen in a study. (cnbc.com)
In new research, scientists reprogrammed skin cells from patients with rare blood disorders into iPSCs, highlighting the great promise of these cells in advancing understanding of those challenging diseases — and eventually in treating them. (sciencedaily.com)
Mutations in FANCL, for instance, cause rare blood disorders and dispose people to cancer. (sciencedaily.com)